C4 Therapeutics, Inc. - 10-Q Filing

C4 Therapeutics filed its Q1 2026 10-Q to provide financial updates and details on operating results, including information about fair value measurements of investments and leasehold assets. The filing also outlines progress under key collaboration agreements with Merck KGaA, Betta Pharmaceuticals, Roche, and Biogen.

SEC EDGAR ·

Tickers: $CCCC

Read the full article at SEC EDGAR

More Regulatory news